Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein GLIS2 (GLIS2) is a nuclear transcription factor belonging to the Krüppel-like family of C2H2-type zinc finger proteins.[1][2][3][4][7] It contains five tandem zinc finger motifs and operates both as a repressor and activator of gene transcription depending on cell context. GLIS2 is critical in the maintenance of normal kidney structure (inhibiting apoptosis and fibrosis), neuronal differentiation, and the regulation of important developmental signaling pathways such as Hedgehog and Wnt.[1][3][4][7] High expression is observed in the kidney, and loss-of-function mutations in GLIS2 cause nephronophthisis type 7 (NPHP7), a genetic kidney disease. Experimental findings support a potential therapeutic role for GLIS2 inhibition in polycystic kidney disease, but it is not currently an established drug target.[6]
Transcriptional repression or activation through direct DNA binding at target gene promoters Pharmacological inhibition (using antisense oligonucleotides) to suppress expression, used experimentally to reduce cyst formation in PKD mouse models[6]
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein GLIS2 (GLIS2).